These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17876040)

  • 21. Buthionine sulphoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines.
    Anderson CP; Tsai J; Chan W; Park CK; Tian L; Lui RM; Forman HJ; Reynolds CP
    Eur J Cancer; 1997 Oct; 33(12):2016-9. PubMed ID: 9516845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of advanced neuroblastoma.
    Evans A; Scher C; D'Angio G
    Eur J Cancer; 1992; 28A(8-9):1301-2. PubMed ID: 1515236
    [No Abstract]   [Full Text] [Related]  

  • 23. Combination of N-(4-hydroxyphenyl) retinamide and genistein increased apoptosis in neuroblastoma SK-N-BE2 and SH-SY5Y xenografts.
    Karmakar S; Choudhury SR; Banik NL; Ray SK
    Neuroscience; 2009 Sep; 163(1):286-95. PubMed ID: 19540315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
    Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S
    Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toxicity of single-day high-dose vincristine, melphalan, etoposide and carboplatin consolidation with autologous bone marrow rescue in advanced neuroblastoma.
    Gordon SJ; Pearson AD; Reid MM; Craft AW
    Eur J Cancer; 1992; 28A(8-9):1319-23. PubMed ID: 1515242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of amifostine on neuroblastoma during high dose chemotherapy: in vivo and in vitro investigations.
    Renner S; Krümpelmann S; Bruchelt G; Wiesinger H; Niethammer D; Klingebiel T
    Anticancer Res; 2000; 20(6B):4531-8. PubMed ID: 11205300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic efficacy of a novel combination therapy controls growth of Bcl-x(L) bountiful neuroblastoma cells by increasing differentiation and apoptosis.
    Mohan N; Banik NL; Ray SK
    Cancer Biol Ther; 2011 Nov; 12(9):846-54. PubMed ID: 21878749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
    Pastorino F; Brignole C; Di Paolo D; Nico B; Pezzolo A; Marimpietri D; Pagnan G; Piccardi F; Cilli M; Longhi R; Ribatti D; Corti A; Allen TM; Ponzoni M
    Cancer Res; 2006 Oct; 66(20):10073-82. PubMed ID: 17047071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
    Pastorino F; Loi M; Sapra P; Becherini P; Cilli M; Emionite L; Ribatti D; Greenberger LM; Horak ID; Ponzoni M
    Clin Cancer Res; 2010 Oct; 16(19):4809-21. PubMed ID: 20702613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute in vivo resistance in high-dose therapy.
    Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
    Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
    Badinloo M; Esmaeili-Mahani S
    Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of chemotherapy resistance genes in outcome of neuroblastoma.
    de Cremoux P; Jourdan-Da-Silva N; Couturier J; Tran-Perennou C; Schleiermacher G; Fehlbaum P; Doz F; Mosseri V; Delattre O; Klijanienko J; Vielh P; Michon J
    Pediatr Blood Cancer; 2007 Mar; 48(3):311-7. PubMed ID: 16609945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
    Croucher JL; Iyer R; Li N; Molteni V; Loren J; Gordon WP; Tuntland T; Liu B; Brodeur GM
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):131-41. PubMed ID: 25394774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma.
    Lindskog M; Spenger C; Jarvet J; Gräslund A; Kogner P
    J Natl Cancer Inst; 2004 Oct; 96(19):1457-66. PubMed ID: 15467035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
    Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
    Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro and in vivo preclinical chemotherapy studies of human neuroblastoma.
    Siegel MM; Chung HS; Rucker N; Siegel SE; Seeger RC; Isaacs H; Benedict WF
    Cancer Treat Rep; 1980; 64(8-9):975-9. PubMed ID: 7448832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma.
    Mao X; Chen Z; Zhao Y; Yu Y; Guan S; Woodfield SE; Vasudevan SA; Tao L; Pang JC; Lu J; Zhang H; Zhang F; Yang J
    Oncotarget; 2017 Jan; 8(1):1555-1568. PubMed ID: 27902463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice.
    Bäckman U; Christofferson R
    Pediatr Res; 2005 May; 57(5 Pt 1):690-5. PubMed ID: 15718357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Combination of Arsenic Trioxide (As
    Yen CM; Tsai CW; Chang WS; Yang YC; Hung YW; Lee HT; Shen CC; Sheu ML; Wang JY; Gong CL; Cheng WY; Bau DT
    Cancer Genomics Proteomics; 2018; 15(6):453-460. PubMed ID: 30343279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy.
    Yoon KJ; Qi J; Remack JS; Virga KG; Hatfield MJ; Potter PM; Lee RE; Danks MK
    Mol Cancer Ther; 2006 Jun; 5(6):1577-84. PubMed ID: 16818517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.